-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $10 Price Target

Benzinga·01/28/2026 17:17:32
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $10 price target.